《新股消息》心通醫療(02160.HK)今日起招股 入場費12,322.94元
由微創醫療(00853.HK)分拆旗下微創心通醫療科技(02160.HK)公布招股詳情,計劃發售2.06億股股份,當中10%在港公開發售,招股價介乎11.1至12.2元,每手1,000股,入場費為12,322.94元。由今日(26日)至本周五(29日)中午公開招股,預計於2月4日上市。摩根大通、花旗及中金為聯席保薦人。
專注於心臟瓣膜疾病領域創新的經導管及手術解決方案的研發和商業化的微創心通醫療是次引入16名基石投資者,包括源峰基金、Hillhouse Funds、GIC、雪湖資本及華夏基金等,合共認購1.25億美元股份。
以招股價中位數11.65元計,公司預計集資淨額為22.48億元,當中30%將用於核心產品VitaFlow II;27%將用於現有產品管線的其他產品;3.4%將用於首款商業化TAVI產品VitaFlow;15%將用於通過併購、授權引進安排或股權投資與包括醫療器械企業及研究機構在內的全球賦能者合作擴展集團產品組合提供資金;14.6%將用於擴大產能並提高生產VitaFlow及VitaFlow II的能力;10%將作營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.